Strategic Partnerships Meridian engages in collaboration with external players such as 4Bases SA to enable rapid and scalable next-generation sequencing workflows, indicating a openness to distribution and co-development opportunities that can be leveraged to expand end-market reach.

NGS Enablement The launch of Lyophilized NGS Enzymatic DNA Fragmentation Kit signals a capability to supply advanced enzymatic reagents and stable formulations for next-generation sequencing workflows, presenting cross-sell opportunities to labs expanding sequencing use cases.

Diagnostics Focus A long track record in immunodiagnostics, antigens, antibodies, blockers and R&D services for in vitro diagnostics, combined with FDA interaction history, suggests strong alignment with diagnostic assay developers seeking reliable reagent supply and contract development.

Manufacturing Scale Commercial-scale production and robust quality systems position Meridian as a potential supplier for high-volume reagent needs, enabling sales conversations around large-scale antibody, antigen, nucleotides and enzyme requirements for commercial diagnostic tests.

R&D and Services Dedicated R&D and Manufacturing teams plus contract development capabilities indicate opportunities to offer customized assay development, process optimization and manufacturing services to expand Meridian’s footprint in partner-driven projects.